Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010–2013

Background. The rollout of the group A meningococcal vaccine, PsA-TT, in Africa's meningitis belt countries represented the first introduction of a vaccine specifically designed for this part of the world. During the first year alone, the number of people who received the vaccine through mass v...

Full description

Bibliographic Details
Main Authors:	Diomandé, Fabien V. K., Yaméogo, Téné M., Vannice, Kirsten S., Preziosi, Marie-Pierre, Viviani, Simonetta, Ouandaogo, Claude-Roger, Keita, Modibo, Djingarey, Mamoudou H., Mbakuliyemo, Nehemie, Akanmori, Bartholomew Dicky, Sow, Samba O., Zuber, Patrick L. F.
Format:	Online
Language:	English
Published:	Oxford University Press 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639501/

id	pubmed-4639501
recordtype	oai_dc
spelling	pubmed-46395012015-11-12 Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010–2013 Diomandé, Fabien V. K. Yaméogo, Téné M. Vannice, Kirsten S. Preziosi, Marie-Pierre Viviani, Simonetta Ouandaogo, Claude-Roger Keita, Modibo Djingarey, Mamoudou H. Mbakuliyemo, Nehemie Akanmori, Bartholomew Dicky Sow, Samba O. Zuber, Patrick L. F. The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa Background. The rollout of the group A meningococcal vaccine, PsA-TT, in Africa's meningitis belt countries represented the first introduction of a vaccine specifically designed for this part of the world. During the first year alone, the number of people who received the vaccine through mass vaccination campaigns was several hundredfold higher than that of subjects who participated in the closely monitored clinical trials. Implementation of a system to identify rare but potentially serious vaccine reactions was therefore a high priority in the design and implementation of those campaigns. Oxford University Press 2015-11-15 2015-11-09 /pmc/articles/PMC4639501/ /pubmed/26553675 http://dx.doi.org/10.1093/cid/civ599 Text en © 2015 World Health Organization; licensee Oxford Journals. http://creativecommons.org/licenses/by/3.0/igo/legalcode This is an open access article distributed under the terms of the Creative Commons Attribution IGO License (http://creativecommons.org/licenses/by/3.0/igo/legalcode), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any reproduction of this article there should not be any suggestion that WHO or this article endorse any specific organization or products. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Diomandé, Fabien V. K. Yaméogo, Téné M. Vannice, Kirsten S. Preziosi, Marie-Pierre Viviani, Simonetta Ouandaogo, Claude-Roger Keita, Modibo Djingarey, Mamoudou H. Mbakuliyemo, Nehemie Akanmori, Bartholomew Dicky Sow, Samba O. Zuber, Patrick L. F.
spellingShingle	Diomandé, Fabien V. K. Yaméogo, Téné M. Vannice, Kirsten S. Preziosi, Marie-Pierre Viviani, Simonetta Ouandaogo, Claude-Roger Keita, Modibo Djingarey, Mamoudou H. Mbakuliyemo, Nehemie Akanmori, Bartholomew Dicky Sow, Samba O. Zuber, Patrick L. F. Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010–2013
author_facet	Diomandé, Fabien V. K. Yaméogo, Téné M. Vannice, Kirsten S. Preziosi, Marie-Pierre Viviani, Simonetta Ouandaogo, Claude-Roger Keita, Modibo Djingarey, Mamoudou H. Mbakuliyemo, Nehemie Akanmori, Bartholomew Dicky Sow, Samba O. Zuber, Patrick L. F.
author_sort	Diomandé, Fabien V. K.
title	Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010–2013
title_short	Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010–2013
title_full	Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010–2013
title_fullStr	Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010–2013
title_full_unstemmed	Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010–2013
title_sort	lessons learned from enhancing vaccine pharmacovigilance activities during psa-tt introduction in african countries, 2010–2013
description	Background. The rollout of the group A meningococcal vaccine, PsA-TT, in Africa's meningitis belt countries represented the first introduction of a vaccine specifically designed for this part of the world. During the first year alone, the number of people who received the vaccine through mass vaccination campaigns was several hundredfold higher than that of subjects who participated in the closely monitored clinical trials. Implementation of a system to identify rare but potentially serious vaccine reactions was therefore a high priority in the design and implementation of those campaigns.
publisher	Oxford University Press
publishDate	2015
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639501/
_version_	1613499262940741632

Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010–2013

Similar Items